We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · December 11, 2019

Management of Adverse Events With Tailored Sorafenib Dosing Prolongs Survival of Patients With HCC

Journal of Hepatology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Hepatology
Management of Adverse Events With Tailored Sorafenib Dosing Prolongs Survival of Hepatocellular Carcinoma Patients
J. Hepatol. 2019 Dec 01;71(6)1175-1183, F Tovoli, L Ielasi, A Casadei-Gardini, A Granito, FG Foschi, G Rovesti, G Negrini, G Orsi, M Renzulli, F Piscaglia

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading